Staff profiles and biographies of Fusion Antibodies staff and board.
Simon's experience in the Biotech industry includes 5 years working for Amersham International, ICI and Zeneca, in a variety of commercial and technical positions, and over 5 years with an LSE listed diagnostic company where he was the Chief Executive and raised £10 million as a rights issue. Most recently he was CEO of the embryonic start up company DNA Research Innovations Ltd (DRI) growing the company during 4 years and completing two rounds of Venture Capital financing. In November 2004, under his leadership, DRI was aquired by the Invitrogen Corporation for $65 million.
With more than 20 years experience in Bioscience and with over 13 years in Fusion Antibodies Ltd in a variety of technical roles, then 10 years in Business Development charged with developing the Contract Research services and seeking partners for the drug assets discovered and validated before joining the board and taking up the Managing Director role in 2011.
Richard has more than 15 years in Bioscience, joining Fusion Antibodies Ltd in 2002 where he was charged with overseeing the Contract Research Services and production of all reagents required for the research and development of the internal drug assets. With over 12 years experience at Fusion Antibodies he accepted the role of Chief Technical Officer and joined the board in 2011, managing all scientific projects and Fusion’s patent portfolios.
Andrew initially joined Fusion in 2010 as a student scientist, but returned in 2012 in a business development role. Andrew is primarily responsible for all daily business development activities at Fusion Antibodies including marketing, advertising, account management, quote generation and business analysis.
Feel free to get in touch for any further information. We would love to hear from you.Contact Us